Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
GMRE
Global Medical REIT
$6.36
Chart
$7.49 (-15.09%)
$8.99 (-29.25%)
$7.94 (-19.90%)
$9.08 (-29.96%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
GMRE
Global Medical REIT
Current Price
$6.36
Login to view Global Medical REIT (GMRE) recommendation from the last 90 days from financial news and social media.
Chart
$7.49 (-15.09%)
$8.99 (-29.25%)
$7.94 (-19.90%)
$9.08 (-29.96%)
GMRE Latest Headlines
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025. WARSAW Ind. May 30 2025 /PRNewswire/ -- Zimmer Biomet Holdings Inc. (NYSE and SIX: ZBH) a global medical technology leader today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2025. The cash...
Today
Olympus Announces Launch of New Endoscope Drying Cabinet. ScopeLocker Air Offers Flexible Size and Air Options for Space-Conscious Facilities. Olympus to Highlight New Drying Cabinet at Annual SGNA Conference CENTER VALLEY Pa. May 29 2025 /PRNewswire/ -- Olympus Corp. a global medical technology company committed to making peoples lives...
Thu May 29, 2025
Olympus Announces FDA Clearance of Its Most Advanced Imaging Endoscopes. EDOF™ Technology Provides a Continuously Sharp Image with Minimal Focal Adjustment as Part of the EVIS X1™ Endoscopy System CENTER VALLEY Pa. May 27 2025 /PRNewswire/ -- Olympus a global medical technology company committed to making peoples lives healthier safer and more...
Tue May 27, 2025
SmithNephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense . SmithNephew (LSE:SN NYSE:SNN) the global medical technology company has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award 10-year. contract for up to $75 million by the United States Department of Defense (DoD) through the Defense Logistics Agency (DLA).
Tue May 27, 2025
Zimmer Biomet Appoints Kevin Thornal as Group President Global Businesses and the Americas. WARSAW Ind. May 27 2025 /PRNewswire/ -- Zimmer Biomet Holdings Inc. (NYSE and SIX: ZBH) a global medical technology leader today announced the appointment of Kevin Thornal as Group President Global Businesses and the Americas. Reporting to Chairman-Elect President and CEO Ivan...
Tue May 27, 2025
RapidSOS and Global Medical Response Collaborate to Cut Critical Minutes from Air Ambulance Dispatch. New innovations unveiled at RapidSOS Innovation Day empower 911 telecommunicators with one-click air ambulance requests and AI-powered automation NEW YORK May 15 2025 /PRNewswire/ -- RapidSOS the intelligent safety company today announced a new agreement with Global Medical Response...
Thu May 15, 2025
RapidSOS and Global Medical Response Collaborate to Cut Critical Minutes from Air Ambulance Dispatch. New innovations unveiled at RapidSOS Innovation Day empower 911 telecommunicators with one-click air ambulance requests and AI-powered automation NEW YORK May 15 2025 /PRNewswire/ -- RapidSOS the intelligent safety company today announced a new agreement with Global Medical Response...
Thu May 15, 2025
Medical Bioreactor Market Set to Surge Reaching USD 7.2 Billion by 2034 | Exactitude Consultancy. Luton Bedfordshire United Kingdom May 15 2025 (GLOBE NEWSWIRE) -- The global medical bioreactor market is valued at approximately $4.1 billion in 2024 and is projected to reach around $7.2 billion by 2034 reflecting a robust CAGR of 6.2% during the forecast period from 2025 to 2034. This growth is fueled by rising demand for biopharmaceuticals alongside breakthroughs in tissue engineering and regen
Thu May 15, 2025
Medical Biopreservation Equipment Market Trends Insights and Future Outlook | Exactitude Consultancy. Luton Bedfordshire United Kingdom May 15 2025 (GLOBE NEWSWIRE) -- The global medical biopreservation equipment market is valued at approximately $3.8 billion in 2024 with projections indicating significant growth anticipating a market value of around $6.2 billion by 2034. This trajectory represents a Compound Annual Growth Rate (CAGR) of 5.0% during the forecast period of 2025 to 2034.Get a Samp
Thu May 15, 2025
Medical Biopreservation Equipment Market Trends Insights and Future Outlook | Exactitude Consultancy. Luton Bedfordshire United Kingdom May 15 2025 (GLOBE NEWSWIRE) -- The global medical biopreservation equipment market is valued at approximately $3.8 billion in 2024 with projections indicating significant growth anticipating a market value of around $6.2 billion by 2034. This trajectory represents a Compound Annual Growth Rate (CAGR) of 5.0% during the forecast period of 2025 to 2034.Get a Samp
Thu May 15, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
GMRE Stock trends
GMRE Stock performance
GMRE Stock analysis
GMRE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
